Nasdaq:US$18.56 (-0.72) | HKEX:HK$29.35 (-0.85) | AIM:£2.90 (-0.15)
新聞中心及演示文稿
上一篇文章   |   下一篇文章
演示文稿, 科學出版物 | 2012-06-01

ASCO 2012: Phase I study of safety and pharmacokinetics of fruquintinib, a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases in patients with advanced solid tumors